Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PanAd3-RSV + MVA-RSV
- Development stage
- Unknown
- Lead developer
- ReiThera
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
PanAd3-RSV + MVA-RSV is an investigational viral-vectored vaccine candidate for respiratory syncytial virus (RSV) infection. The vaccine utilizes a heterologous prime-boost regimen consisting of two components: PanAd3-RSV, a replication-defective chimpanzee-derived adenovirus vector, and MVA-RSV, a modified vaccinia virus Ankara vector. Both vectors are engineered to express three RSV antigens: the fusion (F) protein (in a truncated soluble form, F0ΔTM), the nucleocapsid (N) protein, and the matrix (M2-1) protein. This combination is designed to induce a balanced immune response, including both neutralizing antibodies (humoral immunity) and robust T-cell responses (cellular immunity), without the Th2-biased cytokines associated with vaccine-enhanced respiratory disease. The vaccine has been evaluated in Phase 1 clinical trials for safety and immunogenicity in healthy younger and older adults.
- Other names
- RSV-PanAd3RSV-PanAd-3RSV-PanAd 3RSV-MVAChimpanzee Adenovirus 3 RSV vaccineModified Vaccinia Ankara RSV vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)M2-1 (Respiratory syncytial virus transcription antitermination factor M2-1)RSV N (Respiratory syncytial virus nucleoprotein)
Beyond the preview
Go deeper on PanAd3-RSV + MVA-RSV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PanAd3-RSV + MVA-RSV.